Finally, early clinical studies with bimekizumab, a dual IL‐17A and IL‐17F neutralizing antibody, have shown rapid and profound clinical responses in psoriasis 21 and PsA 20 patients suggesting an unappreciated role for IL‐17F in addition to IL‐17A in promoting inflammation. The gene discussed is IL17A; the disease is psoriasis.